Novo Nordisk Aktie

96,96 EUR +3,21 EUR +3,42 %

20:50:56

FSE

97,13 EUR +2,53 EUR +2,67 %

17:50:06

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.420,65 Mrd. EUR

KGV37,40Div. Rendite1,35%

WKNA3EU6F

ISINDK0062498333

SymbolNONOF

Novo Nordisk Aktien News

Sortieren:Datum Meistgelesen

28.04.23GlobeNewswireNovo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2023

26.04.23GlobeNewswireNovo Nordisk A/S - Articles of Association

26.04.23GlobeNewswireNovo Nordisk A/S – Reduction of the share capital

24.04.23GlobeNewswireNovo Nordisk A/S - share repurchase programme

17.04.23GlobeNewswireNovo Nordisk A/S - share repurchase programme

13.04.23GlobeNewswireNovo Nordisk raises sales and operating profit outlook for 2023

12.04.23GlobeNewswireAspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity

03.04.23GlobeNewswireNovo Nordisk A/S - share repurchase programme

27.03.23GlobeNewswireNovo Nordisk A/S - share repurchase programme

24.03.23GlobeNewswireOral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial

23.03.23GlobeNewswireResolutions from the Annual General Meeting of Novo Nordisk A/S

20.03.23GlobeNewswireNovo Nordisk A/S - share repurchase programme

14.03.23PR NewswireNovo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024

13.03.23GlobeNewswireNovo Nordisk A/S - share repurchase programme

07.03.23GlobeNewswireNovo Nordisk announces changes in Executive Management

06.03.23GlobeNewswireNovo Nordisk A/S – Share repurchase programme

02.03.23GlobeNewswireNovo Nordisk to expand R&D presence in greater Boston area

27.02.23GlobeNewswireNovo Nordisk A/S – Share repurchase programme

22.02.23GlobeNewswireNotice for the Annual General Meeting of Novo Nordisk A/S

16.02.23GlobeNewswireNovo Nordisk A/S - share repurchase programme

14.02.23GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

10.02.23GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

10.02.23GlobeNewswireHeartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 – a cell therapy designed to restore heart function in people with advanced heart failure

01.02.23MyDividendsNovo Nordisk hebt die Dividende das 25. Jahr in Folge an und kauft eigene Aktien zurück

22.11.22GlobeNewswireNovo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark

02.11.22GlobeNewswireNovo Nordisk's sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 128.9 billion in the first nine months of 2022

14.10.22GlobeNewswireNovo Nordisk announces the completion of the Forma Therapeutics acquisition

03.10.22GlobeNewswireOnce-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial

12.09.22GlobeNewswireNovo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence

01.09.22GlobeNewswireNovo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

22.08.22GlobeNewswireNovo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes

03.08.22GlobeNewswireNovo Nordisk's sales increased by 25% in Danish kroner and by 16% at constant exchange rates to DKK 83.3 billion in the first six months of 2022

29.07.22GlobeNewswireNovo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3

07.06.22GlobeNewswireNovo Nordisk A/S:

03.06.22GlobeNewswireNovo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1

06.05.22GlobeNewswireNovo Nordisk A/S:

02.05.22GlobeNewswireNovo Nordisk – major shareholder announcement

29.04.22GlobeNewswireNovo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2022

29.04.22GlobeNewswireNovo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.